A disruptive therapeutic avenue emerged with the occurrence of tyrosine kinase inhibitors (TKIs), which target the critical function of aberrant receptor tyrosine kinase activation in regulating tumor cell growth and metastasis.3 New desire and prolonged survival for patients with advanced or metastatic NSCLC who carried definite genetic abnormalities have been offered by TKIs, and gradually become the standard treatment for these patients. The gene discussed is NTRK1; the disease is non-small cell lung carcinoma.